---
title: "Jasper Completes Kira Acquisition, Raises $132M PIPE and Licenses C5a Programs to Mirador"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293021291.md"
description: "Jasper Therapeutics completed its acquisition of Kira Pharmaceuticals, shifting majority ownership to former Kira holders. Concurrently, Jasper raised $132 million via a PIPE financing and established Contingent Value Rights tied to a potential $30 million Priority Review Voucher for briquilimab. Additionally, Kira licensed its anti-C5a programs to Mirador Therapeutics for a $12 million upfront payment plus significant milestones."
datetime: "2026-07-17T10:13:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293021291.md)
  - [en](https://longbridge.com/en/news/293021291.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293021291.md)
generator: "portal-rs"
---

# Jasper Completes Kira Acquisition, Raises $132M PIPE and Licenses C5a Programs to Mirador

Jasper Therapeutics completed its acquisition of Kira Pharmaceuticals, issuing common and non-voting preferred shares that shift majority ownership to former Kira holders prior to a concurrent financing. Jasper also entered a $132 million PIPE of non-voting preferred stock, granted registration rights to investors, and established a CVR structure that could pay $30 million upon a Priority Review Voucher for briquilimab. Key insiders signed support and 180-day lock-up agreements to facilitate approvals and trading stability. Separately, Kira licensed its anti-C5a and C5aR programs to Mirador for $12 million upfront, with up to $458.5 million in milestones plus royalties.

**Agreement 1: Jasper Therapeutics Acquires Kira Pharmaceuticals in Stock-for-Stock Merger**

-   **Agreement type**: Agreement and Plan of Merger
-   **Counterparty**: Kira Pharmaceuticals
-   **Signed / Effective**: Jul 16 2026 / Jul 16 2026
-   **Duration / Termination**: N/A
-   **Reason**: Expand pipeline and scale via acquisition

**Agreement 2: Jasper Raises $132 Million via PIPE of Non-Voting Preferred Stock**

-   **Agreement type**: Securities Purchase Agreement for $132 million PIPE of non-voting preferred
-   **Counterparty**: Investors
-   **Signed / Effective**: Jul 16 2026 / Jul 20 2026
-   **Duration / Termination**: N/A
-   **Reason**: Strengthen balance sheet and fund growth

**Agreement 3: Jasper Grants Registration Rights for PIPE Investors**

-   **Agreement type**: Registration Rights Agreement for PIPE resale
-   **Counterparty**: Investors
-   **Signed / Effective**: Jul 16 2026 / Jul 16 2026
-   **Duration / Termination**: Until registration obligations are satisfied
-   **Reason**: Provide resale liquidity for PIPE investors

**Agreement 4: Jasper Sets CVR Structure Tied to Potential $30 Million PRV Milestone**

-   **Agreement type**: Contingent Value Rights Agreement for $30 million PRV milestone
-   **Counterparty**: Rights Agent and holders of Jasper common stock of record
-   **Signed / Effective**: Jul 16 2026 / Jul 16 2026
-   **Duration / Termination**: Until milestone payment conditions satisfied
-   **Reason**: Align legacy holders with briquilimab milestone

**Agreement 5: Jasper Secures Voting Support for Post-Merger Stockholder Matters**

-   **Agreement type**: Support Agreements for Company Stockholder Matters
-   **Counterparty**: Certain directors and officers of Jasper
-   **Signed / Effective**: Jul 16 2026 / Jul 16 2026
-   **Duration / Termination**: Until stockholder vote is completed
-   **Reason**: Facilitate approvals for conversion and governance items

**Agreement 6: Jasper and Key Holders Enter 180-Day Lock-Up Following Kira Deal**

-   **Agreement type**: Lock-up Agreements (180-day transfer restrictions)
-   **Counterparty**: Directors, officers and certain stockholders of Jasper and Kira
-   **Signed / Effective**: Jul 16 2026 / Jul 16 2026
-   **Duration / Termination**: 180 days after Closing (subject to early termination conditions)
-   **Reason**: Promote trading stability and alignment post-merger

**Agreement 7: Jasper (via Kira) Licenses C5a/C5aR Programs to Mirador for $12 Million Upfront**

-   **Agreement type**: Exclusive global IP license for anti-C5a and C5aR programs
-   **Counterparty**: Mirador Therapeutics
-   **Signed / Effective**: Jul 13 2026 / Jul 13 2026
-   **Duration / Termination**: Until expiry of last royalty term
-   **Reason**: Monetize non-core assets and focus portfolio

Original SEC Filing: Jasper Therapeutics, Inc. \[ JSPR \] - 8-K - Jul. 16, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [JSPR.US](https://longbridge.com/en/quote/JSPR.US.md)

## Related News & Research

- [Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | JSPR Stock News](https://longbridge.com/en/news/295951622.md)
- [Jasper Therapeutics Q2 loss per share beats estimates, raises $132 mln](https://longbridge.com/en/news/295952283.md)
- [FS KKR Capital hosts shareholder meeting on share issuance proposal vote](https://longbridge.com/en/news/296534123.md)
- [Canopy Growth publishes fiscal 2026 annual report to shareholders](https://longbridge.com/en/news/296098371.md)
- [Phancy Group announces extraordinary general meeting](https://longbridge.com/en/news/296507914.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**